加载中
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
常规交易时段
US$1.10
+US$0.01 · +0.92%
盘中时间采用ET。市场数据可能有所延迟。
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
日内区间
当前US$1.10
52周区间
当前US$1.10
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
强力卖出
估值
20
估值过高
情绪
41
多空交织
风险
98
极高风险
动量
21
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
日内区间
当前US$1.10
52周区间
当前US$1.10
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 50万 USD | — | 2882.6万 USD | −48.3万 USD |
| 销货成本 | 46万 USD | — | 142.3万 USD | 185.6万 USD | — |
| 毛利 | −46万 USD | 50万 USD | −142.3万 USD | 2697万 USD | −48.3万 USD |
| 研究与开发 | 328.6万 USD | — | 142.3万 USD | 1976.7万 USD | 4897.9万 USD |
| 销售、一般及管理费用 | 683.1万 USD | 544.9万 USD | 1265.3万 USD | 1089万 USD | 1308.7万 USD |
| 营业费用 | 965.7万 USD | 1273.2万 USD | 1357.3万 USD | 2880.1万 USD | 6206.6万 USD |
| 利息收入 | 2.9万 USD | 8000 USD | 3.2万 USD | 1.5万 USD | 14.1万 USD |
| 利息支出 | 1000 USD | 1.8万 USD | — | 59.5万 USD | 169.1万 USD |
| 折旧和摊销 | 46万 USD | 82.4万 USD | 137.5万 USD | 185.6万 USD | 177.9万 USD |
| 营业利润 | −1011.7万 USD | −1223.2万 USD | −1499.6万 USD | −183.1万 USD | −6254.9万 USD |
| 净利润 | −494.6万 USD | −970.1万 USD | −1691.4万 USD | −258.2万 USD | −6410.2万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$12.00
上涨空间 990.91%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
